@MsStat2

Updates and insight on the MS-STAT2 study from the team at UCL. A phase 3 clinical trial of high dose simvastatin for secondary progressive multiple sclerosis

 London, England
ms-stat2.info
Joined April 2019
  • Tweets345
  • Following93
  • Followers534
85Media
Today the results of the MS-STAT2 trial were announced by Professor Jeremy Chataway at the ECTRIMS research conference in Copenhagen. This trial tested simvastatin, commonly used to treat high cholesterol, in 964 people with secondary progressive MS. (1/6)
2
7
3
38
3,733
Registration and abstract submission are open for MS Frontiers conference! This year the MS Society are hosting their MS research conference at the University of Liverpool. Find out all about it and how to register via their website: mssociety.org.uk/research/fo…

MS Frontiers

MS Frontiers is our biennial research conference bringing together researchers and clinicians. The next conference is taking place at the University of Edinburgh on the 18th and 19th of June 2026.

mssociety.org.uk
2
180
Thank you @StuStepsUp+Marie for inspiring work @mssocietyuk @mscymru Ambassadors for people with #MS #AdvancedMS Check out chariotms.com #ChariotMS @QSMSCENTRE @MsStat2 @OctopusTrial @AttackMS_trial @the_MSBlog #MS @RachelHorne19 @themsguide @aid4disabled #NHS75 #GIG75
Welsh NHS Confederation@WelshConfed5 Jul 2023
Recently retired nurse & general manager and MS ambassador @StuStepsUp talks candidly about his experience of working in the NHS with MS over the last 40 years and how demand has changed vastly over that time. #NHS75 #GIG75
1
6
18
1,372
Excellent @EANeurology #EAN2023 update on our expanded knowledge of #MS CNS compartmentalised inflammation and the exciting near future of BTK Inhibitors by Wallace Brownlee, Veronica Popescu and Martin König @DrWBRO @VeroPopescu
1
4
5
863
Great to be in Budapest for #EAN2023 discussing PIRA, compartmentalized CNS inflammation and BTK inhibitors with Veronica Popescu and Marton König @VeroPopescu @EANeurology
7
44
3,748
What is MS progression? Our understanding of progress independent of disease activity (PIRA) has grown over the last 20 years, with clinical and real world studies confirming that once relapses are controlled with DMTs progression can still happen!
1
9
428
An excellent overview of #SMOULDERINGMS - how we see progression independent of relapses #PIRA, what processes are involved and what #biomarkers will let us ultimately lead to individualized treatment!
1
4
314
#BrainAtrophy and #CognitiveImpairment in #MS - Closely interlinked, and of great importance to PWMS. Cognitive impairment being associated with more care needs and worse quality of life - focus on slowing/stopping this is essential!
3
7
420
#BigData in #MS - a great overview of the incorporation of all the -omics (genomic, metabolomics, proteomics, etc) towards novel understanding and treatments for #PMS #ProgressiveMS
2
6
325
#BigData in #MS - so many exciting opportunities to dive deeper into phenotypes, personalised assessments, and enhance clinical trials!
3
10
544
The European Academy of Neurology 2023 conference! Let's talk #MS #BigData #Biomarkers #SmoulderingMS #clinicaltrials #PIRA and much more!
3
252
Hot off the press! The first STAT2 research paper - Cardiovascular Risk Factors in SPMS and how they impact brain volumes and memory. onlinelibrary.wiley.com/doi/… Thank you to all our participants for their time and contribution!

Cardiovascular risk factors in secondary progressive multiple sclerosis: A cross‐sectional analysis...

Background and purpose There is increasing evidence that cardiovascular risk (CVR) contributes to disability progression in multiple sclerosis (MS). CVR is particularly prevalent in secondary...

onlinelibrary.wiley.com
3
18
3
29
4,028
#MSAwarenessWeek - how does MS make you feel? Does it affect you personally, or someone you know? Our amazing colleague Dr Alessia Bianchi @alessia_bia completing the London marathon to fundraiser for the @mssocietyuk! If you'd like please donate via: 2023tcslondonmarathon.enthus…
1
1
14
742
Higher serum neurofilament light chain (sNfL) is linked to more cognitive decline in MS. Data from the MS-STAT study (simvastatin vs. placebo in progressive MS) pubmed.ncbi.nlm.nih.gov/3594…
2
8
34
Serum neurofilament light and MRI predictors of cognitive decline in patients with secondary progressive multiple sclerosis: Analysis from the MS-STAT randomised controlled trial - PubMed pubmed.ncbi.nlm.nih.gov/3594…

Serum neurofilament light and MRI predictors of cognitive decline in patients with secondary...

Elevated sNfL is associated with faster cognitive decline, independent of T2LV and regional normalised volumes.

pubmed.ncbi.nlm.nih.gov
7
27
How did we recruit all our fantastic volunteers with SPMS for the MS-STAT2 and MS-SMART trials?? How can we make it better?! All in here if interested 👇 trialsjournal.biomedcentral.…

Optimising recruitment in clinical trials for progressive multiple sclerosis: observational...

Trials - Slower than planned recruitment is a major factor contributing to the delay or failure of randomised controlled trials to report on time. There is a limited evidence base regarding the...

link.springer.com
1
5
12
😂😂
Helen Ford@Helenlouiseford8 Jul 2022
#MSFrontiers Let’s stop MS Together @SwanseaUni for the bi-annual @mssocietyuk research meeting with Jeremy Chataway @QSMSCENTRE @MsStat2
1
Fantastic to have team MS-STAT2 at #MSFrontiers! Congratulations to ⁦⁦@mssocietyuk⁩ for a brilliant conference in beautiful Swansea!
1
1
20
Rachael Hunter presenting fascinating but quite shocking data on the impact of #SPMS on employment and quality of life for people in MS-STAT2. This is why we need treatments!
7
21
Fantastic to have ⁦@judy_beveridge⁩ talking about patient and public involvement in MS-STAT2 😊😊
1
1
6
Load more